Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
22. November 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
21. November 2022 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA’s Orange Book
18. November 2022 14:45 ET
|
Avadel Pharmaceuticals plc
- Delisting of REMS Patent sets path to potentially accelerate final approval by FDA DUBLIN, Ireland, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a...
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
10. November 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results
09. November 2022 07:30 ET
|
Avadel Pharmaceuticals plc
LUMRYZ™ granted tentative approval on July 18, confirming its safety profile and clinical efficacyFinal approval decision of LUMRYZ expected by June 2023; advancing strategy to potentially accelerate...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07. November 2022 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9
02. November 2022 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022
24. Oktober 2022 16:05 ET
|
Avadel Pharmaceuticals plc
- Results identify mood, sleep and pain disorders as the most common comorbidities in people living with narcolepsy - - Encore presentations at ANA 2022 reinforce positive data from completed Phase...
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
22. September 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
07. September 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...